Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Change in cognitive biomarkers assessed by DTI
研究概览
简要总结
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
PD-R
Parkinson's disease receiving rasagiline
干预措施: Rasagiline (Drug)
结局指标
主要结局
Change in cognitive biomarkers assessed by DTI
时间窗: 2.5 years
Comparison of change in cognitive biomarkers with change in MMSE and MoCA scores
时间窗: 2.5 years
次要结局
- Comparison of Baseline plasma BDNF with magnitude of change in brain cognitive biomarkers and MMSE and MoCA scores(2.5 years)
- Comparison of changes in plasma BDNF with changes in brain cognitive biomarkers and MMSE and MoCA scores(2.5 years)
研究者
Thomas Guttuso
Associate Professor of Neurology, Obstetrics & Gynecology
State University of New York at Buffalo